JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1996; 28:1031-1038
© 1996 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, R.
Right arrow Articles by Miller, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, R.
Right arrow Articles by Miller, W.

C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems

RS Wright, CM Wei, CH Kim, M Kinoshita, Y Matsuda, LL Aarhus, JC Burnett Jr, and WL Miller

Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

OBJECTIVES: We tested the hypothesis that C-type natriuretic peptide (CNP) mediates coronary vasodilation through activation of cyclic guanosine monophosphate (cGMP) by way of particulate guanylate cyclase. BACKGROUND: CNP has known peripheral vasodilator properties, and preliminary data have suggested that it can function as a coronary vasodilator. METHODS: The actions of CNP were studied in instrumented dogs and in organ chamber rings in the presence and absence of a known antagonist to particulate guanylate cyclase, HS-142-1. Additionally, the actions of HS-142-1 were tested on acetylcholine-mediated coronary vasodilation, and immunohistochemical staining was utilized to localize the presence of CNP in the coronary endothelium. RESULTS: CNP relaxed isolated coronary arteries with (mean +/- SEM 45.9 +/- 7%*) and without (72.0 +/- 7%*) an endothelium (*p < 0.05 for CNP effect alone, p < 0.05 for endothelium vs. no endothelium with CNP). Intracoronary infusions increased coronary blood flow (baseline, 64.6 +/- 5.1 ml/min; CNP-5, 79.9 +/- 6.1*; CNP-20, 103.3 +/- 13.6* [*p < 0.05 vs. baseline value]) and reduced coronary vascular resistance (baseline, 1.6 +/- 0.3 mm Hg/ml per min; CNP-5, 1.4 +/- 0.3*; CNP-20, 1.2 +/- 0.3*). Intracoronary injections increased coronary blood flow (delta baseline coronary flow, 30 +/- 9* ml/min [*p < 0.05]). HS-142-1 significantly attenuated these increases (delta coronary flow, 30 +/- 9* ml/min [CNP] to 14 +/- 6 [CNP + HS-142-1] [p < 0.05 CNP vs. CNP + HS-142-1]) and the relaxation of organ chamber rings (56 +/- 7% [CNP] to 18 +/- 6% [HS-142-1 + CNP]). Finally, CNP was localized to the coronary endothelium and smooth muscle by immunohistochemical staining. CONCLUSIONS: CNP functions as a coronary vasodilator through activation of cGMP by way of particulate guanylate cyclase. CNP-mediated coronary vasodilation is attenuated by intracoronary HS-142-1. Intracoronary HS-142-1 does not affect acetylcholine-mediated coronary vasodilation. These observations support a role for exogenous CNP as a potent coronary vasodilator.


This article has been cited by other articles:


Home page
CirculationHome page
A. Hobbs, P. Foster, C. Prescott, R. Scotland, and A. Ahluwalia
Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury: Novel Cardioprotective Role for Endothelium-Derived C-Type Natriuretic Peptide
Circulation, September 7, 2004; 110(10): 1231 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Lakshminrusimha, C. A. D'Angelis, J. A. Russell, L. C. Nielsen, S. F. Gugino, P. A. Nickerson, and R. H. Steinhorn
C-type natriuretic peptide system in fetal ovine pulmonary vasculature
Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L361 - L368.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. D. Intengan and E. L. Schiffrin
Vasopeptidase Inhibition Has Potent Effects on Blood Pressure and Resistance Arteries in Stroke-Prone Spontaneously Hypertensive Rats
Hypertension, June 1, 2000; 35(6): 1221 - 1225.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Hirose, Y. Furukawa, Y. Miyashita, F. Kurogouchi, K. Nakajima, M. Tsuboi, and S. Chiba
CNP causes receptor-mediated positive dromotropic effects in anesthetized dog hearts
Am J Physiol Heart Circ Physiol, August 1, 1998; 275(2): H717 - H720.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Itoh, I. M. Bird, K. Nakao, and R. R. Magness
Pregnancy Increases Soluble and Particulate Guanylate Cyclases and Decreases the Clearance Receptor of Natriuretic Peptides in Ovine Uterine, But Not Systemic, Arteries
Endocrinology, July 1, 1998; 139(7): 3329 - 3341.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y.-P. Fan, S. Chakder, and S. Rattan
Inhibitory Effect of Zinc Protoporphyrin IX on Lower Esophageal Sphincter Smooth Muscle Relaxation by Vasoactive Intestinal Polypeptide and Other Receptor Agonists
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 468 - 474.
[Abstract] [Full Text]


Home page
HypertensionHome page
G. Barletta, C. Lazzeri, S. Vecchiarino, R. Del Bene, G. Messeri, A. Dello Sbarba, M. Mannelli, and G. La Villa
Low-Dose C-Type Natriuretic Peptide Does Not Affect Cardiac and Renal Function in Humans
Hypertension, March 1, 1998; 31(3): 802 - 808.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1996 by the American College of Cardiology Foundation.